Casdin Capital LLC Sells 120,000 Shares of Illumina, Inc. $ILMN

Casdin Capital LLC lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 18.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 525,000 shares of the life sciences company’s stock after selling 120,000 shares during the period. Illumina comprises 4.2% of Casdin Capital LLC’s portfolio, making the stock its 7th largest position. Casdin Capital LLC’s holdings in Illumina were worth $49,859,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Quent Capital LLC acquired a new stake in shares of Illumina during the 3rd quarter valued at approximately $29,000. Aster Capital Management DIFC Ltd bought a new position in Illumina during the third quarter worth $33,000. Mather Group LLC. acquired a new position in Illumina in the third quarter worth $46,000. SJS Investment Consulting Inc. boosted its holdings in Illumina by 13,225.0% in the third quarter. SJS Investment Consulting Inc. now owns 533 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 529 shares during the period. Finally, Evelyn Partners Investment Management LLP increased its stake in Illumina by 4,927.3% during the second quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock valued at $49,000 after purchasing an additional 542 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $118.94 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The firm has a market capitalization of $18.19 billion, a PE ratio of 21.82, a P/E/G ratio of 2.28 and a beta of 1.45. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53. The business’s fifty day moving average price is $133.15 and its two-hundred day moving average price is $119.96.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the previous year, the company posted $0.95 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. TD Cowen reissued a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Guggenheim lifted their price target on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Stifel Nicolaus boosted their price objective on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. UBS Group reiterated a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research note on Friday, February 6th. Finally, Barclays raised their target price on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Six analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus price target of $129.69.

Insider Transactions at Illumina

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.60% of the stock is owned by insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.